Pure Global

Bioequivalence Study Between YHP2205 and YHR2401 in Healthy Volunteers - Trial NCT06359626

Access comprehensive clinical trial information for NCT06359626 through Pure Global AI's free database. This Phase 1 trial is sponsored by Yuhan Corporation and is currently Not yet recruiting. The study focuses on Healthy Volunteers. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06359626
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06359626
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Bioequivalence Study Between YHP2205 and YHR2401 in Healthy Volunteers
An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2-period, Crossover Study to Evaluate Bioequivalence Between YHP2205 and YHR2401 in Healthy Subjects

Study Focus

Healthy Volunteers

YHP2205

Interventional

drug

Sponsor & Location

Yuhan Corporation

Timeline & Enrollment

Phase 1

May 27, 2024

Jul 06, 2024

60 participants

Primary Outcome

Area under the plasma drug concentration-time curve [AUCt],Maximum plasma concentration [Cmax]

Summary

A randomized, open-label, single-dose, 2-sequence, 2-period, crossover clinical trial to
 investigate the bioequivalence between YHP2205 and YHR2401 in healthy volunteers

ICD-10 Classifications

Healthy person accompanying sick person
Routine general health check-up of armed forces
Routine general health check-up of sports teams
Routine general health check-up of inhabitants of institutions

Data Source

ClinicalTrials.gov

NCT06359626

Non-Device Trial